13. Statins (HMG-CoA Reductase Inhibitors)
Statins are among the rare drugs that may actually benefit the gut flora — linked to a richer, more balanced microbiota that partly offsets obesity-related dysbiosis.
Statins – A Fungal Discovery That Changed Cardiovascular Medicine
Statins are among the most prescribed drugs in the world — and one of the few medication classes where population-level data suggest a net neutral-to-positive effect on gut microbial diversity. [240]
In 1971, a Japanese biochemist named Akira Endo was working at the Sankyo pharmaceutical company in Tokyo with a specific and counterintuitive hypothesis: if bacteria depend on isoprenoid pathways for cell membrane integrity, some fungi may have evolved inhibitors of these pathways as competitive weapons against bacterial rivals. Endo and his team screened over 6,000 fungal strains over three years. In 1973, they isolated mevastatin — later called compactin — from a blue-green mould contaminating a grain sample from Kyoto: Penicillium citrinum. The compound turned out to inhibit not bacterial membrane synthesis but the human enzyme HMG-CoA reductase, the rate-limiting step in hepatic cholesterol biosynthesis. Mevastatin was shelved following early animal toxicity concerns, but the chemical class was real. By 1987, Merck launched lovastatin, the first commercially available statin. Today, an estimated 200 million people take a statin daily. What their prescribers and patients rarely discuss is that the organisms Endo originally had in mind — bacteria — are precisely the community most shaped by decades of chronic statin exposure in the gut.
Statins lower LDL cholesterol by competitively inhibiting hepatic HMG-CoA reductase. The gut lumen receives significant drug exposure before hepatic first-pass extraction. At luminal concentrations that may substantially exceed plasma levels, statins interact with gut microbiota through at least three distinct mechanisms: direct antimicrobial activity, indirect modulation of the bile acid pool, and suppression of intestinal inflammatory tone.
Statins possess intrinsic antimicrobial properties, particularly against gram-positive bacteria. Simvastatin, atorvastatin, and lovastatin inhibit the growth of Staphylococcus aureus, Enterococcus faecalis, and selected Streptococcus species by disrupting isoprenoid synthesis pathways required for bacterial cell membrane integrity. At luminal concentrations — where statin exposure is prolonged by enterohepatic recirculation — the selective pressure on gram-positive commensal communities may be clinically relevant.
The bile acid pathway is a second, indirect mechanism. Statins reduce hepatic cholesterol availability, altering the composition and volume of primary bile acids entering the gut. Primary bile acids are the exclusive substrate for microbial conversion to secondary bile acids (deoxycholic acid, lithocholic acid) — a process carried out by Clostridiales and Lachnospiraceae. Secondary bile acids regulate gut ecosystem composition as both antimicrobial agents and signalling molecules for nuclear receptors FXR[G] and TGR5[G]. Statin-induced changes in the primary bile acid pool propagate downstream as changes in microbial community ecology.
A landmark study by Vieira-Silva et al. published in Nature in 2020 analysed gut microbiota data from 888 participants in two independent Belgian cohorts. Statin use was independently associated with higher gut microbial richness, enrichment of Bacteroidetes, and a microbiota profile consistent with a favourable cardiometabolic signature. Crucially, statin users showed an attenuated microbiome–BMI association: obese patients on statins had a less dysbiotic gut microbiota than obese non-users — suggesting that statins may partially offset gut dysbiosis associated with metabolic disease. [240]
In the context of FMT treatment, statin use is not a contraindication. The available evidence suggests a net neutral-to-beneficial effect on gut ecology in most patients. However, statins create a pre-existing microbiota signature — mild enrichment of Bacteroidetes and modest reduction in some gram-positive butyrate producers — that may modulate engraftment dynamics. Patients on long-term statin therapy should be identified in the pre-FMT medication review; dose continuity is maintained throughout all treatment phases.
Managing Gut Health During Statin Therapy
In clinical microbiota care, statin use is classified as potentially modifying rather than actively harmful. The primary tasks are documentation of the statin type, dose, and duration, and monitoring for symptoms that may reflect statin–microbiota interactions.
Patients on statins who experience persistent gastrointestinal symptoms — particularly altered bowel frequency, bloating, or cramping — should have microbiota context evaluated. These symptoms are often attributed to direct statin toxicity but may also reflect disruption of gram-positive commensal communities in individuals with pre-existing dysbiosis.
Co-prescription of statins with antibiotics or proton pump inhibitors should be flagged in the pre-FMT medication review. The combined microbiota impact may exceed the sum of individual effects, particularly when statin-induced bile acid shifts are compounded by acid suppression or direct antimicrobial disruption.
Dietary fibre intake ≥25g/day and regular fermented food consumption support the SCFA-producing communities that statins modestly reduce and maximise the observed cardiometabolic benefits of the statin–microbiota interaction.
Microbiota Effects
- Statin use is associated with higher gut microbial richness and Bacteroidetes enrichment in population cohorts, particularly among obese and cardiometabolic patients. [240]
- Statins exert intrinsic antimicrobial activity against gram-positive bacteria through inhibition of isoprenoid membrane synthesis, modestly reducing some Firmicutes-associated butyrate producers at luminal concentrations. [241]
- Statin-induced reduction in hepatic primary bile acid output alters secondary bile acid production by Clostridiales, reshaping microbial community structure through FXR and TGR5 receptor-mediated signalling. [242]
- Atorvastatin and simvastatin are associated with enrichment of Lactobacillaceae and reduction of Enterobacteriaceae in hypercholesterolaemic patients, consistent with reduced intestinal inflammatory tone. [241]
- The net gut microbiota effect of statins appears modestly favourable in cardiometabolic patients — a rare distinction among commonly prescribed medication classes. [240]
- In post-FMT patients, statin continuation is appropriate; the clinical question is understanding the pre-existing statin-modified microbiota baseline and its interaction with donor engraftment trajectory. [243]
- Statin-associated myopathy has been mechanistically linked in some investigations to altered microbiota-mediated secondary bile acid signalling, though this remains under active investigation. [244]
Patient Guidance
- Continue statins as prescribed throughout FMT treatment — do not modify statin doses based on gut symptom concerns without explicit physician guidance.
- Maintain dietary fibre intake of ≥25g/day to support SCFA-producing communities that statins modestly reduce.
- Include fermented foods (yogurt, kefir, fermented vegetables) regularly to sustain community balance alongside statin therapy.
- Report persistent gastrointestinal symptoms during statin use to your clinical team — some statin GI effects reflect microbiota dynamics rather than direct drug toxicity.
- Avoid combining statin therapy with unnecessary antibiotic courses — the combined disruption of bile acid ecology and antimicrobial pressure exceeds that of either agent alone.
- If your statin type or dose changes during FMT consolidation, notify the clinical team — altered bile acid dynamics may affect engraftment trajectory.
References
[240] Vieira-Silva S, Falony G, Belda E et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature. 2020. Link
This study used quantitative faecal metagenomes from the MetaCardis Body Mass Index Spectrum cohort (n=888) to examine the obesity-associated Bacteroides2 (Bact2) enterotype, characterized by high Bacteroides, low Faecalibacterium and low microbial cell density. Statin therapy emerged as a key covariate of microbiome diversification. In the non-statin subcohort, Bact2 prevalence rose from 3.90% in lean/overweight to 17.73% in obese individuals. Bact2 carriers had higher systemic inflammation than predicted by obesity alone, marking Bact2 as a dysbiotic constellation linked to obesity and inflammation, with statins potentially modulating this association.
[241] Yoo BB, Mazmanian SK. The Enteric Network: Interactions between the Immune and Nervous Systems of the Gut. Immunity. 2017. Link
This review describes how the enteric nervous system (ENS) translates chemical cues from diet, pathogens and microbiota into neuronal signals that propagate through the gut and to the CNS. Emerging literature establishes the ENS as essential for microbe-induced mucosal immune responses. The authors emphasize the proximity of the ENS to immune cells and luminal interface and propose this neuro-immune interface as a novel paradigm for nervous system research. The findings underscore the ENS as a central integrator of gut-microbiota-immune signalling.
[242] Gérard, P. Gut microbiota and obesity. Cell Mol Life Sci. 2016. Link
This review summarizes mechanistic and clinical evidence that the gut microbiota contributes to obesity and associated metabolic disorders. Germ-free animal experiments and microbiota transplants demonstrate a causal role in adiposity and energy harvest, with multiple identified mechanisms. Humans show consistent differences in microbiota composition, functional genes and metabolic activity between obese and lean individuals. The authors propose microbiota modulation as a novel therapeutic and preventive strategy in obesity.
[243] Zimmermann M et al. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019. Link
This study measured the ability of 76 human gut bacteria from diverse clades to metabolize 271 orally administered drugs and showed many drugs are chemically modified by gut microbes. High-throughput genetics and mass spectrometry systematically identified microbial gene products that metabolize drugs. These microbiome-encoded enzymes substantially affected intestinal and systemic drug metabolism in mice and explained the drug-metabolizing activities of human gut communities by genomic content. The findings causally connect microbiome composition to interpersonal differences in drug metabolism with implications for therapy and drug development.
[244] Mafra D et al. Dietary components that may influence the disturbed gut microbiota in chronic kidney disease. Nutrients. 2019. Link
This review discusses nutritional strategies to modulate gut microbiota in chronic kidney disease (CKD), where dysbiosis associates with increased uremic toxins, inflammation, oxidative stress and cardiovascular morbimortality. Proteins, fibres, probiotics, synbiotics and bioactive compounds such as polyphenols and curcumin emerge as key dietary modulators. Available human CKD trials are limited, preventing firm prioritization. The authors call for targeted nutritional intervention studies to alleviate gut dysbiosis in CKD and reduce its clinical sequelae.